Giovannalberto Pini

Dr. Giovannalberto Pini

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in European Urology
Verified
Journal Article
Closed access
MRMaria J Ribal
Maria J Ribal
PCPhilip Cornford
Philip Cornford
ABAlberto Briganti
Alberto Briganti
TKThomas Knoll
Thomas Knoll
SGStavros Gravas
Stavros Gravas
JNJames N’dOw
James N’dOw

1 July 2015 in European Urology
Verified
Journal Article
Open access
RARiccardo Autorino
Riccardo Autorino
HZHomayoun Zargar
Homayoun Zargar
MMMirandolino B. Mariano
Mirandolino B. Mariano
RSRafael Sanchez-Salas
Rafael Sanchez-Salas
RSRené J. Sotelo
René J. Sotelo
FPFrancesco Porpiglia
Francesco Porpiglia
Laparoscopic and robotic simple prostatectomy (SP) have been introduced with the aim of reducing the morbidity of the standard open technique. To report a large multi-institutional series of minimally invasive SP (MISP). Consecutive cases of MISP done for the treatment of bladder outlet obstruction (BOO) due to benign prostatic enlargement (BPE) between 2000 and 2014 at 23 participating institutions in the Americas and Europe were included in this retrospective analysis. Laparoscopic or robotic SP. Demographic data and main perioperative outcomes were gathered and analyzed. A multivariable analysis was conducted to identify factors associated with a favorable trifecta outcome, arbitrarily defined as a combination of the following postoperative events: International Prostate Symptom Score 15ml/s, and no perioperative complications. Overall, 1330 consecutive cases were analyzed, including 487 robotic (36.6%) and 843 laparoscopic (63.4%) SP cases. Median overall prostate volume was 100ml (range: 89-128). Median estimated blood loss was 200ml (range: 150-300). An intraoperative transfusion was required in 3.5% of cases, an intraoperative complication was recorded in 2.2% of cases, and the conversion rate was 3%. Median length of stay was 4 d (range: 3-5). On pathology, prostate cancer was found in 4% of cases. Overall postoperative complication rate was 10.6%, mostly of low grade. At a median follow-up of 12 mo, a significant improvement was observed for subjective and objective indicators of BOO. Trifecta outcome was not significantly influenced by the type of procedure (robotic vs laparoscopic; p=0.136; odds ratio [OR]: 1.6; 95% confidence interval [CI], 0.8-2.9), whereas operative time (p=0.01; OR: 0.9; 95% CI, 0.9-1.0) and estimated blood loss (p=0.03; OR: 0.9; 95% CI, 0.9-1.0) were the only two significant factors. Retrospective study design, lack of a control arm, and limited follow-up represent major limitations of the present analysis. This study provides the largest outcome analysis reported for MISP for BOO/BPE. These findings confirm that SP can be safely and effectively performed in a minimally invasive fashion in a variety of healthcare settings in which specific surgical expertise and technology is available. MISP can be considered a viable surgical treatment in cases of large prostatic adenomas. The use of robotic technology for this indication can be considered in centers that have a robotic program in place for other urologic indications. Analysis of a large data set from multiple institutions shows that surgical removal of symptomatic large prostatic adenomas can be carried out with good outcomes by using robot-assisted laparoscopy.

1 April 2018 in European Urology
Verified
Journal Article
Closed access
PSPrasanna Sooriakumaran
Prasanna Sooriakumaran
GPGiovannalberto Pini
Giovannalberto Pini
TNTommy Nyberg
Tommy Nyberg
MDMaryam Derogar
Maryam Derogar
SCStefan Carlsson
Stefan Carlsson
PWPeter N. Wiklund
Peter N. Wiklund

1 November 2010 in European Urology
Verified
Journal Article
Closed access
MHMarcel Hruza
Marcel Hruza
HWHagen O. Weiß
Hagen O. Weiß
GPGiovannalberto Pini
Giovannalberto Pini
AGAli S. Goezen
Ali S. Goezen
MSMichael Schulze
Michael Schulze
JRJens J. Rassweiler
Jens J. Rassweiler

6 June 2012 in BJU International
Verified
Journal Article
Closed access
PDF file
CSChristopher Springer
Christopher Springer
MHM. Raschid Hoda
M. Raschid Hoda
HFHarun Fajkovic
Harun Fajkovic
GPGiovannalberto Pini
Giovannalberto Pini
NMNasreldin Mohammed
Nasreldin Mohammed
FGFrancesco Greco
Francesco Greco

25 August 2015 in Scandinavian Journal of Urology
Verified
Journal Article
Closed access
PDF file
JCJustin W. Collins
Justin W. Collins
CAChristofer Adding
Christofer Adding
AHAbolfazl Hosseini
Abolfazl Hosseini
TNTommy Nyberg
Tommy Nyberg
GPGiovannalberto Pini
Giovannalberto Pini
PWPeter N. Wiklund
Peter N. Wiklund
Objective: The aim of this study was to assess the effect of introducing an enhanced recovery programme (ERP) to an established robot-assisted radical cystectomy (RARC) service. Materials and methods: Data were prospectively collected on 221 consecutive patients undergoing totally intracorporeal RARC between December 2003 and May 2014. The ERP was specifically designed to support an evolving RARC service, where increasing proportions of patients requiring radical cystectomy underwent RARC. Patient demographics and outcomes before and after implementation of the ERP were compared. The primary endpoint was length of stay (LOS). Secondary outcomes included age, American Society of Anesthesiologists (ASA) score, preoperative staging, operative time, complications and readmissions. Differences in outcomes between patients before and after implementation of ERP were tested with the Jonckheere–Terpstra trend test and quantile regression with backward selection. Results: Following implementation of the ERP, the demographics of the patients (n = 135) changed, with median age increasing from 66 to 70 years (p < 0.01), higher ASA grade (p < 0.001), higher preoperative stage cancer (pT ≥ 2, p < 0.05) and increased likelihood of undergoing an ileal conduit diversion (p < 0.001). Median LOS before ERP was 9 days [interquartile range (IQR) 8–13 days] and after ERP was 8 days (IQR 6–10 days) (p < 0.001). ASA grade and neoadjuvant chemotherapy also affected LOS (p < 0.05 and p < 0.01, respectively). There was no significant difference in 30 day complication rates, readmission rates or 90 day mortality, with 59% experiencing complications before ERP implementation and 57% after implementation. The majority of complications were low grade. Conclusions: Patient demographics changed as the RARC service evolved from selected patients to a general service. Despite worsening demographics, LOS decreased following ERP implementation. This evidence-based ERP safely standardized perioperative care, resulting in decreased LOS and decreased variability in LOS.